Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HOOK NASDAQ:MCRB NASDAQ:MEIP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHOOKHOOKIPA Pharma$1.18$1.11$0.81▼$1.77$14.55M0.8411,102 shs13,645 shsMCRBSeres Therapeutics$7.76-2.5%$8.56$6.53▼$29.98$77.08M0.1257,710 shs35,440 shsMEIPMEI Pharma$3.19+14.7%$3.98$1.92▼$9.00$104.72M0.38919,067 shs3.98 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHOOKHOOKIPA Pharma0.00%0.00%+2.61%+14.56%-13.87%MCRBSeres Therapeutics-2.51%-3.00%-9.56%-5.60%+5.29%MEIPMEI Pharma0.00%0.00%0.00%0.00%+52.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHOOKHOOKIPA Pharma$1.18$1.11$0.81▼$1.77$14.55M0.8411,102 shs13,645 shsMCRBSeres Therapeutics$7.76-2.5%$8.56$6.53▼$29.98$77.08M0.1257,710 shs35,440 shsMEIPMEI Pharma$3.19+14.7%$3.98$1.92▼$9.00$104.72M0.38919,067 shs3.98 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHOOKHOOKIPA Pharma0.00%0.00%+2.61%+14.56%-13.87%MCRBSeres Therapeutics-2.51%-3.00%-9.56%-5.60%+5.29%MEIPMEI Pharma0.00%0.00%0.00%0.00%+52.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHOOKHOOKIPA Pharma 0.00N/AN/AN/AMCRBSeres Therapeutics 2.00Hold$22.00183.51% UpsideMEIPMEI Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MCRB, HOOK, and MEIP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2026MCRBSeres Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)3/13/2026MCRBSeres Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.00(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHOOKHOOKIPA Pharma$9.35M1.56N/AN/A$4.25 per share0.28MCRBSeres Therapeutics$1.15M65.52$1.06 per share7.33$2.74 per share2.83MEIPMEI PharmaN/AN/A$6.25 per share0.51$4.96 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHOOKHOOKIPA Pharma-$43.50M-$3.54N/AN/AN/A-785.66%-120.09%-77.14%N/AMCRBSeres Therapeutics$5.70M-$5.17N/AN/AN/AN/A-130.29%-35.35%N/AMEIPMEI Pharma$17.78M-$4.75N/AN/AN/AN/A-77.00%-64.79%N/ALatest MCRB, HOOK, and MEIP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q1 2026MCRBSeres Therapeutics-$1.88-$2.08-$0.20-$2.08$0.36 million$0.36 million3/12/2026Status updateMCRBSeres Therapeutics-$2.39-$1.89+$0.50-$1.76N/A$0.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHOOKHOOKIPA PharmaN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/AMEIPMEI PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHOOKHOOKIPA PharmaN/A3.613.61MCRBSeres TherapeuticsN/A1.651.65MEIPMEI PharmaN/A16.7816.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHOOKHOOKIPA Pharma63.88%MCRBSeres Therapeutics59.34%MEIPMEI Pharma52.38%Insider OwnershipCompanyInsider OwnershipHOOKHOOKIPA Pharma3.30%MCRBSeres Therapeutics4.70%MEIPMEI Pharma3.12%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHOOKHOOKIPA Pharma16012.33 million11.79 millionOptionableMCRBSeres Therapeutics3309.68 million9.23 millionOptionableMEIPMEI Pharma10032.84 million31.81 millionOptionableMCRB, HOOK, and MEIP HeadlinesRecent News About These CompaniesMEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS’September 11, 2025 | theglobeandmail.comMEI Pharma to change name to Lite StrategySeptember 10, 2025 | msn.comMEI Pharma leaves biotech woes behind to rebrand as crypto companySeptember 10, 2025 | fiercebiotech.comFMEI Pharma Secures Loan Agreement with BitGo PrimeSeptember 4, 2025 | msn.comMEI Pharma Welcomes New Board Member Joshua RiezmanAugust 11, 2025 | theglobeandmail.comMEI Pharma files to sell 25.3M shares of common stock for holdersAugust 7, 2025 | msn.comMEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR AdvisingAugust 5, 2025 | joplinglobe.comJMEI Pharma’s Strategic Shift with Litecoin TreasuryJuly 25, 2025 | theglobeandmail.comMEI Pharma's Bold Bet: First Public Company to Go All-In on Litecoin TreasuryJuly 25, 2025 | econotimes.comPublic Shell Firms Ramping Up Altcoin Buys Draws Skepticism: FTJuly 25, 2025 | coindesk.comBTC digital asset field continues to exert its strength, HASHJ launches Bitcoin cloud mining platform with "capital + technology" dual-driven modeJuly 24, 2025 | thenewswire.comTMEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National ExchangeJuly 22, 2025 | businesswire.comMEI Pharma (MEIP) Becomes the First and Only Publicly Traded LTC Holder on a National ExchangeJuly 20, 2025 | msn.comMEI Pharma Unveils $100M Litecoin Treasury PlanJuly 19, 2025 | livebitcoinnews.comLGSR leads $100M private placement into Nasdaq-listed MEI Pharma to launch Litecoin treasuryJuly 18, 2025 | coinjournal.netMEI Pharma Shares Surge After Unveiling $100 Million Litecoin Treasury PlanJuly 18, 2025 | msn.comMEI Pharma Stock Surges on $100M Private Placement, Litecoin Treasury StrategyJuly 18, 2025 | marketwatch.comMEI Pharma Commits $100M to Litecoin Treasury Strategy: Can LTC Price 10x?July 18, 2025 | blockonomi.comNasdaq-listed MEI Pharma launches $100M Litecoin treasury plan, stock rockets 50%July 18, 2025 | cryptobriefing.comCLitecoin Price Forecast: LTC reclaims $100 as NASDAQ-listed MEI Pharma unveils $100 million treasuryJuly 18, 2025 | fxstreet.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMCRB, HOOK, and MEIP Company DescriptionsHOOKIPA Pharma NASDAQ:HOOK$1.18 0.00 (0.00%) As of 05/13/2026 01:07 PM EasternHOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Seres Therapeutics NASDAQ:MCRB$7.76 -0.20 (-2.51%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$7.82 +0.06 (+0.82%) As of 05/13/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.MEI Pharma NASDAQ:MEIPMEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Upside Expands as AI Feedback Loop Intensifies Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? D-Wave Earnings Looked Weak, But Investors May Be Missing This A Quantum Shift: Why Speculative Money Is Ditching AI Plug Power Flips The Switch On Profitability Reading the Stripes: Is The Industrial Recession Over? How Bad Could Tesla’s Cybertruck Recall Be for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
